Advertisement

Cellceutix Corporation (OTCBB: CTIX) will launch its first human trial for its lead product, a potential therapy for advanced solid tumors at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, after a nine-month delay.

Advertisement
Advertisement